The neurotechnology company INBRAIN Neuroelectronics, a member of CATALONIA.HEALTH, has received a 4 million euros’ grant from the Spanish Ministry of Industry and Tourism through the PERTE Chip initiative, a national programme to support the most revolutionary innovation in microelectronics, semiconductors and deeptech. With this investment, the company is promoting the development of the graphene-based precision brain-computer interface (BCI) technology to modify and modulate brain activity in real time for the treatment of neural diseases.
INBRAIN has developed the world’s first neural graphene interface for the treatment of central nervous system (CNS) diseases. This technology has already been successfully tested in cancer patients, and proofs of concept have also been published with promising results in applications for epilepsy, Parkinson’s disease and stroke.
The PERTE Chip initiative aims to strengthen, from an integral perspective, the design and production capacities of the Spanish microelectronics and semiconductor industry, while promoting strategic technological autonomy, both for Spain.
Carolina Aguilar, CEO and co-founder of INBRAIN Neuroelectronics, explained: “This grant will allow us to accelerate the mission of developing precision nanotechnologies capable of transforming the treatment of neurological diseases, while contributing to position Spain at the forefront of innovation in deep technology for health care.”
Related news:
Comments